美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NETLease Corporate Real Estate ETF

26.80

+0.19010.71%

成交量：1,451

成交額：3.89萬

市值：5,561.02萬

市盈率：- -

高：26.81

開：26.81

低：26.80

收：26.61

52周最高：28.43

52周最低：23.56

股本：207.50萬

流通股本：207.50萬

量比：0.24

換手率：0.07%

股息：1.25

股息率：4.67%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

藥明合聯 2026 年上半年業績：業務穩步推進，利潤率與盈利規模持續提升，夯實全球ADC/XDC CRDMO 領先地位

基石藥業-B(02616)：CS5007(EGFR/HER3雙特異性ADC)IND申請獲中國NMPA批准

燦芯股份發布28nm高性能SAR ADC IP

新加坡基地BCM3雙功能產線成功完成GMP放行，以專業實力賦能全球客户

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/NETL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":26.8001,"timestamp":1787590274694,"preClose":26.61,"halted":0,"volume":1451,"delay":0,"changeRate":0.007143930853062798,"floatShares":2075000,"shares":2075000,"eps":0,"marketStatus":"交易中","change":0.1901,"latestTime":"08-24 13:01:09 EDT","open":26.8094,"high":26.8094,"low":26.8,"amount":38856.876027,"amplitude":0.000353,"askPrice":27,"askSize":100,"bidPrice":26.4,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":26.61,"sharesOutstanding":1775000,"nav":26.69,"aum":55381750,"dividendRate":0.046668,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.61,"preClose":26.61,"latestTime":"16:10 EDT","volume":8,"amount":212.88,"timestamp":1787343004768,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.244997,"impliedVol":0.0372,"impliedVolPercentile":0.008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":2075000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.244997,"shares":2075000,"dividePrice":1.2507,"high":26.8094,"amplitude":0.000353,"preClose":26.61,"low":26.8,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":26.8001,"eps":0,"divideRate":0.046668,"volume":1451,"delay":0,"ttmEps":0,"open":26.8094,"prevYearClose":23.727,"prevWeekClose":26.61,"prevMonthClose":27.14,"prevQuarterClose":26.7001,"fiveDayClose":26.48,"twentyDayClose":27.9307,"sixtyDayClose":26.3675},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"},{"date":"2026-03-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-27","defaultRemindTime":1774618200000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-27","currency":"USD","dateTimestamp":1774584000000,"payDate":"2026-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662438270","title":"藥明合聯 2026 年上半年業績：業務穩步推進，利潤率與盈利規模持續提升，夯實全球ADC/XDC  CRDMO 領先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2662438270","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662438270?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 20:35","pubTimestamp":1787574900,"startTime":"0","endTime":"0","summary":"毛利及毛利率  2026年上半年，本集团毛利同比增长40.6%至13.71亿元人民币，毛利率为37.0%，较2025年上半年提升0.9个百分点。经调整归属母公司净利润及其利润率  2026年上半年，经调整归属母公司净利润同比增长37.4%，至10.27亿元人民币，彰显了本集团核心经营业务强劲的利润增长势头。2026年上半年客户和项目亮点  本集团持续扩大客户群，累计客户数达814家。值得注意的是，截至报告期末，本集团累计完成超过22,000个ADC/XDC分子的研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5032132_ZH32132_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5032132_ZH32132_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["NETL","BK4080","LU2488822045.USD","SG9999014674.SGD","BK4231","BK1141","ADC","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661306402","title":"基石藥業-B(02616)：CS5007(EGFR/HER3雙特異性ADC)IND申請獲中國NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661306402","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661306402?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 06:08","pubTimestamp":1787263715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司管线2.0核心候选药物之一CS5007的新药临床试验申请，已通过中国国家药品监督管理局创新药临床试验审评审批通道快速获得批准，全程仅用23个工作日。此前，CS5007的全球多中心I期临床试验已于2026年6月在澳大利亚启动并完成首例患者入组，该项试验也将同步在中国开展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1161","NETL","BK1574","ADC","IND","BK4080","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407386","title":"燦芯股份發布28nm高性能SAR ADC IP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 16:51","pubTimestamp":1787215892,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4231","IE00B3T34201.USD","LU1481599808.USD","LU1169590202.USD","LU1169589451.USD","BK4585","ADC","WOOD","CUT","BK4135","SAR","BK4588","IP","LU2463526074.USD","LU1481600234.SGD","BK4080","LU1487256676.USD","BK4136","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660307451","title":"新加坡基地BCM3雙功能產線成功完成GMP放行，以專業實力賦能全球客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2660307451","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660307451?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 11:59","pubTimestamp":1787025540,"startTime":"0","endTime":"0","summary":"药明合联新加坡基地BCM3双功能产线成功实现GMP放行  作为公司海外首个通过GMP放行的产能设施，BCM3产线采用高效灵活的\"双功能\"设计理念，提供从抗体中间体到偶联原液的全流程一站式商业化生产服务。根据新加坡基地后续产线建设规划，其制剂生产线DP4亦将于2026年8月底完成GMP放行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5028415_ZH28415_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5028415_ZH28415_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["SG9999014674.SGD","ADC","BK4231","BK1141","BK4080","LU2488822045.USD","NETL","02268"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NETL\",params:#limit:6,delay:false,,,undefined,":[]}}